Positive Data Update from Ph 1 Clinical Trial of ELVN-001 in CML Announced
“We are excited by the continued advancement of the ELVN-001 Phase 1 trial, and we remain confident in ELVN-001’s potential to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “With more patients enrolled and longer follow up, we continue to see anti-CML activity in a heavily pre-treated patient population that includes patients previously treated with asciminib. Additionally, ELVN-001’s safety profile remains consistent with its high selectivity, even with longer duration and more patients enrolled at higher dose levels. We believe the data demonstrate the potential clinical utility of ELVN-001 for patients across the full spectrum of the CML treatment paradigm.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000